Pasithea Therapeutics Corp. KTTA

- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004,

-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) -- MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases inc

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 -- Full abstract will be published on ESMO website per Congress’ standard embargo schedule MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next

July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunologyMIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neu

-- Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and gastrointestinal toxicities -- Protocol Amendment Extends Dose Escalation to Higher Levels: Continued dose escalation using tablet formulation to explore 18mg, 24mg, 30mg, 40mg, and up to 52mg dose levels to further characterize safety, pharmacokineti

-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it has amended the clinical study protocol for the Phase 1/1b trial of PAS-004 in neurofibromatosis type 1 (NF1) patients with symptom

-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting with Pasithea are encouraged to contact in advance to schedule – MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced it wil

Orphan Drug Designation is intended to support the development of therapies for rare diseases affecting fewer than 200,000 people in the United StatesMIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PAS-004 for the treatment o

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (CMO) of the Company, effective May 1, 2026. Dr. Krishnan will oversee all clinical development and medical strategy as the Company advances PAS-004 through the clinic for the treatment of neur

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV)MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to PAS-004 for treatment of Neurofibromatosis type-1 (NF1). Th

Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or life-threatening conditionMIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food an

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheim

MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients. Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565